Canaccord Genuity analyst Elyse Shapiro maintained a Buy rating on Cogstate Ltd (COGZF – Research Report) on October 26 and set a price target of A$2.10. The company’s shares closed last Friday at $0.91.
Shapiro covers the Healthcare sector, focusing on stocks such as Impedimed Limited, Mayne Pharma Group, and Cogstate Ltd. According to TipRanks, Shapiro has an average return of -19.1% and a 14.29% success rate on recommended stocks.
Currently, the analyst consensus on Cogstate Ltd is a Moderate Buy with an average price target of $1.33.
See today’s best-performing stocks on TipRanks >>
COGZF market cap is currently $162.6M and has a P/E ratio of 44.17.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cogstate Ltd (COGZF) Company Description:
Cogstate Ltd is a cognitive science company. The principal activity of the company is a sale of technology and services for the measurement of cognition, where services include scientific consultancy, project management, data management, statistical analysis and reporting. Its operating segment includes Clinical Trials; Healthcare and Research. The company generates maximum revenue from the Clinical Trials segment. In clinical trials segment, technology and services are sold to pharmaceutical, biotechnology, nutraceutical, and functional food companies.
